Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
In a media release on Jan. 22, it was revealed that a group of scientists from the Agency for Science, Technology and ...
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Yeah, so the EGFR mutation lung cancer ...
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...
When the team knocked out the P2Y2 receptor in drug-resistant cancer cells, it led to an almost complete loss of the mutant EGFR protein.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results